Neuphoria Therapeutics (NEUP) Total Current Liabilities (2021 - 2026)

Neuphoria Therapeutics (NEUP) has reported Total Current Liabilities for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 2.5% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 2.5% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, up 10.23% from the prior year.
• Total Current Liabilities was $1.5 million for Q1 2026 at Neuphoria Therapeutics, down from $2.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $5.1 million in Q3 2025 and troughed at $1.5 million in Q1 2026.
• A 5-year average of $2.9 million and a median of $2.6 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 100.82% in 2025 and retreated 2.5% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $2.4 million in 2022, then rose by 14.83% to $2.8 million in 2023, then slipped by 22.69% to $2.1 million in 2024, then climbed by 21.21% to $2.6 million in 2025, then plunged by 41.49% to $1.5 million in 2026.
• The last three Total Current Liabilities figures came in at $1.5 million (Q1 2026), $2.6 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.